Spondyloarthropathies News

Treatment with secukinumab resulted in better response rates and a lower cost per responder compared with adalimumab among patients with psoriatic arthritis in the United States, according to findings presented at the American College of Rheumatology Annual Meeting.

The FDA has released a draft guidance for industry outlining criteria for demonstrating that a biosimilar is interchangeable with a reference product under section 351 (k) of the Public Health Service Act.

Certolizumab pegol demonstrated continued improvements in disease activity during a 4-year period among patients with axial spondyloarthritis, according to data presented at the American College of Rheumatology Annual Meeting.

Smoking cessation was associated with lower disease activity, improved physical function and better quality of life in patients with axial spondyloarthritis, according to a recently published study.

CMS has included payment information for Inflectra, the FDA-approved biosimilar to Janssen’s Remicade, in its January Average Selling Price pricing file, Pfizer announced.

In patients with axial spondyloarthropathy, depression appears to have a negative impact on quality of life and function, though it is not associated with advanced structural disease, according to findings presented at the American College of Rheumatology Annual Meeting.

The use of apremilast over 3 years demonstrated sustained response and improvements in patients with psoriatic arthritis whose symptoms included swollen and tender joint counts, enthesitis, dactylitis and psoriasis, according to study results presented at the American College of Rheumatology Annual Meeting.

Janssen Biotech Inc. announced it has submitted two FDA supplemental biologics license applications for golimumab in the treatment of ankylosing spondylitis and psoriatic arthritis, according to a press release.

Treatment with tofacitinib improved sacroiliac joint and spine scores among patients with ankylosing spondylitis and resulted in more patients achieving minimum clinically important differences compared with placebo, according to findings presented at the American College of Rheumatology Annual Meeting.

Precision medicine is rapidly racing forward and, for those of us who are watching, it may be reasonable to ask “What will this mean for me?” The most obvious question might be whether we should seek to be early adopters or lay low and wait for the dust to settle.